Approval Of BMS/Bluebird’s Ide-Cel May Come Just In Time
Manufacturing Inspection Delays Could Impact Decision Due 27 March
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.
